Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 3/20 | 0.51 |
| ▸ | S100A4 | P26447 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4585399 | 0.88 | PTPRC (0.50) | PTPRCS100A4ALDH1A1CYP3A4TDP1 | |
| SCHEMBL4606460 | 0.85 | PTPRC (0.47) | PTPRCS100A4ALDH1A1TDP1BCHE | |
| SCHEMBL503711 | 0.80 | HSP90AA1 (0.55) | PTPRCS100A4ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL4586774 | 0.80 | POLB (0.62) | PTPRCS100A4ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL28643490 | 0.79 | TSHR (0.59) | PTPRCS100A4ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL5707981 | 0.79 | PTPRC (0.56) | PTPRCS100A4ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL7824186 | 0.76 | ALDH1A1 (0.68) | PTPRCS100A4ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL10605676 | 0.76 | ALDH1A1 (0.68) | PTPRCS100A4ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL13743283 | 0.75 | HSP90AA1 (0.53) | ALDH1A1CYP3A4ALOX15TDP1CES2 | |
| SCHEMBL130412 | 0.74 | DTYMK (0.64) | ALDH1A1CYP3A4ALOX15TDP1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096848-A1 | N-(2-(1H-Pyrazol-1-yl)-phenyl)-9H-fluorene-1-carboxamide for example; treating proliferative diseases such as cancer, viral diseases, inflammatory bowel disease, rheumatoid arthritis, psoriasis; combination therapy with other known anticancer drugs | CYTOVIA INC. (CA) | 2008-04-24 | — | — | US | disclosed |
| EP-1804786-A4 | SUBSTITUTED N-ARYL-9-OXO-9H-FLUORENE-1-CARBOXAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1804786-A2 | SUBSTITUTED N-ARYL-9-OXO-9H-FLUORENE-1-CARBOXAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Cytovia, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006039356-A2 | SUBSTITUTED N-ARYL-9-OXO-9H-FLUORENE-1-CARBOXAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA, INC. (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096848-A1 | N-(2-(1H-Pyrazol-1-yl)-phenyl)-9H-fluorene-1-carboxamide for example; treating proliferative diseases such as cancer, viral diseases, inflammatory bowel disease, rheumatoid arthritis, psoriasis; combination therapy with other known anticancer drugs | CASP1, CASP9, CASP14 | PTPRC 2666/4885S100A4 1903/4885ALDH1A1 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.